Mark Donovan

Senior Director of Biostatistics
Bristol Myers Squibb, Inc.

Presentation(s):

• OC 15.1 - PREVAPIX-ALL: Phase 3 Study of the Safety and Efficacy of Apixaban for Thromboprophylaxis versus Standard of Care in Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia or Lymphoma (ALL/LL)

  Sunday, July 10, 2022
  10:45 AM – 11:00 AM